Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America
October 21 2019 - 8:15AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that the Lupus Foundation of America will be
recognizing their CEO Ron Rocca at the upcoming Evening of Hope
Gala October 28.
“We are humbled by this honor and grateful to the many internal
and external clinical and scientific collaborators who contributed
to the development of the AVISE® CTD panel,” said Ron Rocca,
President and CEO of Exagen Inc. “We are closely aligned with the
LFA in their mission to reduce the time to an accurate diagnosis of
lupus, which is a key contributor to better control of the disease.
It is not acceptable that it takes an average of 6 years for
an accurate diagnosis, or that lupus is the leading cause of death
among women aged 15-24 with chronic inflammatory disease. Today we
celebrate this recognition of our collective achievement, but
tomorrow we are back to the tireless work to help solve the cruel
mystery of lupus.”
“We are proud to honor Ron Rocca and the work of Exagen in their
development of the AVISE CTD panel which can help doctors diagnose
lupus,” shared Stevan W. Gibson, president and CEO, Lupus
Foundation of America. “Reducing the time to diagnosis is an
incredibly important part of our mission, and because of the work
of Exagen under Mr. Rocca’s leadership, we are getting more people
diagnosed and treated earlier, which is critical to preventing
long-term consequences of the disease.”
Rheumatologists across the country are now using the patented
AVISE CTD panel to quickly get the answers they need in determining
if a patient has systemic lupus erythematosus (SLE) or one of the
many other conditions that can mimic the disease. Once accurately
diagnosed, lupus patients may benefit from the AVISE SLE Monitor
panel, a blood test to help uncover disease progression, organ
involvement, risk of thrombosis, as well as optimization of
hydroxychloroquine, the most widely prescribed therapy for SLE. For
more information on AVISE testing visit www.avisetest.com .
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis. Exagen’s laboratory testing
facility is CAP accredited, CLIA certified.
Forward-Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding: the results of these
clinical utility studies validating the AVISE Lupus test and the
potential to lead to increased adoption of the AVISE Lupus test;
and the ability of the AVISE Lupus test to help physicians improve
their ability to diagnose and manage patients suspected of an
autoimmune disease and provide net savings to the healthcare
system. The inclusion of forward-looking statements should
not be regarded as a representation by Exagen that any of its plans
will be achieved. Actual results may differ from those set forth in
this press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: Exagen’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; if third-party payers do not
provide coverage and adequate reimbursement for Exagen’s testing
products, or they breach, rescind or modify their contracts or
reimbursement policies or delay payments for its testing products
or promoted therapeutics, or if Exagen or its partners are unable
to successfully negotiate payer contracts, Exagen’s commercial
success could be compromised; and other risks described in the
Company’s prior press releases and in the Company’s filings with
the Securities and Exchange Commission, including under the heading
"Risk Factors" in the Company’s Registration Statement on Form S-1
and any subsequent filings with the SEC. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and we undertake no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, which
is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
CONTACTS:
Westwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838 Exagen Inc. Brian
McEvillybmcevilly@exagen.com760.560.1506
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024